Source comparison
PT-141 vs Vyleesi: Side-by-Side Comparison
Active Ingredient Bremelanotide 1.75mg Bremelanotide 1.75mg (reconstituted from lyophilized powder) Pharmacologically identical. Same molecule, same dose FDA Approval Status FDA-approved finished drug product Not FDA-approved. Compounded under state pharmacy o
This comparison does not assign a generated winner or score.
- Active Ingredient
- Bremelanotide 1.75mg
- Bremelanotide 1.75mg (reconstituted from lyophilized powder)
- Pharmacologically identical. Same molecule, same dose
- FDA Approval Status
- FDA-approved finished drug product
- Not FDA-approved. Compounded under state pharmacy oversight
- Vyleesi has formal FDA batch oversight; PT-141 relies on compounder reputation
- Cost per Dose
- $800–$900 (cash price without insurance)
- $80–$150 (typical compounded pricing)
- PT-141 is 80–90% cheaper. Cost is the primary access differentiator
- Delivery Format
- Pre-filled autoinjector pen (single-use)
- Lyophilized powder in vial. Patient reconstitutes and draws dose
- Vyleesi is more convenient; PT-141 requires reconstitution skill
- Insurance Coverage
- Sometimes covered with prior authorization
- Rarely covered. Considered off-label compounded medication
- Vyleesi has better insurance access if plan covers sexual health medications
- Quality Oversight
- GMP manufacturing + FDA batch release testing
- USP 797 sterile compounding + voluntary third-party COAs
- Vyleesi has guaranteed oversight; PT-141 quality depends on compounder